Abstract 50P
Background
Emerging data suggest that an immune checkpoint inhibitor in combination with chemotherapy is a reasonable strategy for advanced biliary tract cancer (aBTC). Apatinib, an oral TKI selectively targeting VEGFR2 has been shown to reshape the immune microenvironment and enhance the efficacy of camrelizumab (an anti-PD-1 antibody) in several cancers. We therefore designed this study to explore the efficacy and safety of apatinib plus Cam and GP in aBTC and especially the optimal dose of apatinib in this strategy.
Methods
This prospective, 2-part, dose escalation and expansion study enrolled patients (pts) with aBTC. Pts would receive Cam (200mg) and GP (gemcitabine 1000mg/m2 and cisplatin 25mg/m2, iv, d1 and d8; up to 6 cycles) plus apatinib in 21-day cycles. In the phase Ib, a 3+3 dose-escalation design is used to determine the recommended phase 2 dose (RP2D) of apatinib (250 mg, qd; A: d1-d7, B: d1-d10, C: d1-d14). Phase II-dose expansion part is to evaluate the primary endpoint of objective response rate (ORR).
Results
As of April 2024, 17 pts had been treated with a median age of 56 years (range 40-71) and 12 were females. Of 9 pts in phase Ib, 7 had stable disease (SD) and 2 had partial response (PR). No DLTs were reported, and PR was only observed in cohort C. Therefore, the RP2D of apatinib in combination with Cam + GP was defined as 250 mg, d1-d14 and 8 pts were enrolled in phase II. 3 pts (37.5%) achieved PR in this phase. With a median follow-up of 3 months (range, 1-5), 6 pts remained response. Best response and the most common TEAEs are summarized in the following table. Table: 50P
Cohort | A | B | C | Total |
Dose frequency of apatinib (q3w) | d1-d7 | d1-d10 | d1-d14 | |
N | 3 | 3 | 3 + 8 | 17 |
Responses | ||||
Objective response rate (CR + PR), n/N (%) | 1/3(33) | 2/3(67) | 5/11(45) | 8/17(47) |
Disease control (CR + PR + SD), n/N (%) | 3/3(100) | 3/3(100) | 11/11(100) | 17/17(100) |
TEAEs, n (%) | ||||
Alanine aminotransferase increased | 2(67) | 3(100) | 11(100) | 16(94) |
Aspartate aminotransferase increased | 2(67) | 3(100) | 11(100) | 16(94) |
Platelet count decreased | 3(100) | 3(100) | 10(91) | 16(94) |
White blood cell decreased | 2(67) | 3(100) | 9(82) | 14(82) |
Neutrophil count decreased | 1(33) | 3(100) | 9(82) | 14(82) |
Nausea | 2(67) | 1(33) | 7(64) | 11(65) |
Malaise | 2(67) | 2(67) | 7(64) | 11(65) |
Alopecia | 2(67) | 2(67) | 7(64) | 11(65) |
Grade ≥3 | 3(100) | 3(100) | 8(73) | 14(82) |
Conclusions
The efficacy signal support apatinib 250 mg, d1-d14 as an optimal dose when in combination with GP and Cam in aBTC. This combination strategy showed modest efficacy and tolerable adverse events in aBTC. The trial is still recruiting and more data would be further analyzed and reported.
Clinical trial identification
NCT05742750.
Editorial acknowledgement
Guiqin Su, Xiaoqiang Fang (Jiangsu Hengrui Pharmaceuticals Co., Ltd.) provided editorial assistance.
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1988P - Enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE study
Presenter: Tanya Jindal
Session: Poster session 13
1989P - Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis
Presenter: Albert Jang
Session: Poster session 13
1990P - MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study
Presenter: Chuanliang Cui
Session: Poster session 13
1992P - Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (NAC)
Presenter: Hedyeh Ebrahimi
Session: Poster session 13
1993P - A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option
Presenter: Anishka D'Souza
Session: Poster session 13
1994P - Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in ≥ second line in metastatic urothelial carcinoma (mUC)
Presenter: Bradley McGregor
Session: Poster session 13
1995P - Insights into second-line (2L) systemic treatment (tx) receipt in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
Presenter: Günter Niegisch
Session: Poster session 13
1996P - Primary analysis of post-marketing surveillance (PMS) data for avelumab maintenance therapy in patients (pts) with curatively unresectable urothelial carcinoma (UC) in Japan
Presenter: Eiji Kikuchi
Session: Poster session 13
1997P - Novel biomarker, ephrinB2 (B2), predicts resistance to treatment and poor overall survival (OS) metastatic urothelial carcinoma (mUC)
Presenter: Sarmad Sadeghi
Session: Poster session 13